{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:39:35Z","timestamp":1773661175909,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tuberculosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.tube.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T16:34:48Z","timestamp":1411144488000},"page":"708-711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Thioridazine for treatment of tuberculosis: Promises and pitfalls"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5066-3342","authenticated-orcid":false,"given":"Noton K.","family":"Dutta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2014.09.001_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tube.2010.03.003","article-title":"Tuberculosis drug development: progress, challenges, and the road ahead","volume":"90","author":"Ginsberg","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.tube.2014.09.001_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0255-0857.99481","article-title":"Tuberculosis chemotherapy: present situation, possible solutions, and progress towards a TB-free world","volume":"30","author":"Dutta","year":"2012","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.tube.2014.09.001_bib3","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: the need and the reality","volume":"375","author":"Ma","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2014.09.001_bib4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1440-1843.2010.01775.x","article-title":"Current development and future prospects in chemotherapy of tuberculosis","volume":"15","author":"Nuermberger","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.tube.2014.09.001_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.00749-08","article-title":"New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development","volume":"53","author":"van den Boogaard","year":"2009","journal-title":"Antimicrobial Agents Chemother"},{"issue":"1","key":"10.1016\/j.tube.2014.09.001_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.12459","article-title":"Tuberculosis drug discovery and emerging targets","volume":"1323","author":"Mdluli","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tube.2014.09.001_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/AAC.46.2.267-274.2002","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective","volume":"46","author":"Gillespie","year":"2002","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jac\/dks405","article-title":"Is repositioning of drugs a viable alternative in the treatment of tuberculosis?","volume":"68","author":"Palomino","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1472-9792(08)70028-3","article-title":"Thioridazine","volume":"88","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.tube.2014.09.001_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157489111796064533","article-title":"Global clinical trials for the treatment of TB with thioridazine","volume":"6","author":"Boeree","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.tube.2014.09.001_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijantimicag.2009.12.019","article-title":"Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!","volume":"35","author":"Amaral","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2014.09.001_bib12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.5588\/ijtld.12.0616","article-title":"The added effect of thioridazine in the treatment of drug-resistant tuberculosis","volume":"16","author":"Amaral","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2014.09.001_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/157489111796064588","article-title":"Thioridazine: the good and the bad","volume":"6","author":"Thanacoody","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.tube.2014.09.001_bib14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jac\/38.6.1049","article-title":"Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis","volume":"38","author":"Amaral","year":"1996","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/47.5.505","article-title":"Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy","volume":"47","author":"Amaral","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/138945006777709539","article-title":"\u201cNon-Antibiotics\u201d: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries","volume":"7","author":"Amaral","year":"2006","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.tube.2014.09.001_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0924-8579(00)00199-0","article-title":"Comparative in\u00a0vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis","volume":"16","author":"Bettencourt","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2014.09.001_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.47.3.917-922.2003","article-title":"Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis","volume":"47","author":"Ordway","year":"2003","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijantimicag.2006.10.013","article-title":"In\u00a0vitro and ex\u00a0vivo activity of thioridazine derivatives against Mycobacterium tuberculosis","volume":"29","author":"Martins","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2014.09.001_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1099\/00221287-63-1-41","article-title":"Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis","volume":"63","author":"Winder","year":"1970","journal-title":"J\u00a0Gen Microbiol"},{"key":"10.1016\/j.tube.2014.09.001_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1128\/AAC.2.1.29","article-title":"Effect of isoniazid on the in\u00a0vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis","volume":"2","author":"Takayama","year":"1972","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib22","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1128\/AAC.49.11.4778-4780.2005","article-title":"Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates","volume":"49","author":"Xie","year":"2005","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib23","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1128\/JB.01857-07","article-title":"Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration","volume":"190","author":"Sohaskey","year":"2008","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.tube.2014.09.001_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/157489111796064551","article-title":"Latent tuberculosis: is there a role for thioridazine?","volume":"6","author":"Sohaskey","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.tube.2014.09.001_bib25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/jac\/dku036","article-title":"Novel non-neuroleptic phenothiazines inhibit Mycobacterium tuberculosis replication","volume":"69","author":"Salie","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib26","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1128\/AAC.00829-13","article-title":"Thioridazine pharmacokinetic-pharmacodynamic parameters \u201cWobble\u201d during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners","volume":"57","author":"Musuka","year":"2013","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib27","series-title":"Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy","author":"de Knegt","year":"2014"},{"key":"10.1016\/j.tube.2014.09.001_bib28","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1128\/AAC.02981-14","article-title":"Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis","volume":"58","author":"Dutta","year":"2014","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0924-8579(00)00343-5","article-title":"Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines","volume":"17","author":"Viveiros","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2014.09.001_bib30","doi-asserted-by":"crossref","first-page":"e10069","DOI":"10.1371\/journal.pone.0010069","article-title":"Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine","volume":"5","author":"Dutta","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2014.09.001_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/157489111796064597","article-title":"New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective","volume":"6","author":"Dutta","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.tube.2014.09.001_bib32","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1073\/pnas.0711697105","article-title":"The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2014.09.001_bib33","doi-asserted-by":"crossref","first-page":"40174","DOI":"10.1074\/jbc.M406796200","article-title":"The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action","volume":"279","author":"Boshoff","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.tube.2014.09.001_bib34","doi-asserted-by":"crossref","first-page":"11456","DOI":"10.1074\/jbc.M508844200","article-title":"Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2)","volume":"281","author":"Yano","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.tube.2014.09.001_bib35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/654820","article-title":"Mycobacterium tuberculosis MT2816 encodes a key stress-response regulator","volume":"202","author":"Mehra","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.tube.2014.09.001_bib36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/652497","article-title":"Genetic requirements for the survival of tubercle bacilli in primates","volume":"201","author":"Dutta","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.tube.2014.09.001_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01066-13","article-title":"Systems biology-based identification of Mycobacterium tuberculosis persistence genes in mouse lungs","volume":"5","author":"Dutta","year":"2014","journal-title":"MBio"},{"key":"10.1016\/j.tube.2014.09.001_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","article-title":"Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism","volume":"145","author":"Adams","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tube.2014.09.001_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tube.2014.09.001_bib40","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkn070","article-title":"Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis","volume":"61","author":"Rodrigues","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib41","doi-asserted-by":"crossref","first-page":"e34538","DOI":"10.1371\/journal.pone.0034538","article-title":"Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis","volume":"7","author":"Machado","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2014.09.001_bib42","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/jac\/dkl500","article-title":"Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps","volume":"59","author":"Amaral","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib43","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jac\/dkt037","article-title":"Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis","volume":"68","author":"Dutta","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib44","first-page":"771","article-title":"The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis","volume":"21","author":"Martins","year":"2007","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.tube.2014.09.001_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012640","article-title":"The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis","volume":"5","author":"van Soolingen","year":"2010","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.tube.2014.09.001_bib46","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.03408-14","article-title":"Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine TB","volume":"58","author":"Dutta","year":"2014","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib47","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1128\/AAC.02293-13","article-title":"Energy metabolism and drug efflux in Mycobacterium tuberculosis","volume":"58","author":"Black","year":"2014","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkr500","article-title":"Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine","volume":"67","author":"Abbate","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157489111796064614","article-title":"Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB","volume":"6","author":"Udwadia","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.tube.2014.09.001_bib50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CMR.00042-10","article-title":"HIV and tuberculosis: a deadly human syndemic","volume":"24","author":"Kwan","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.tube.2014.09.001_bib51","doi-asserted-by":"crossref","first-page":"e1002464","DOI":"10.1371\/journal.ppat.1002464","article-title":"Tuberculosis and HIV co-infection","volume":"8","author":"Pawlowski","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2014.09.001_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00010-14","article-title":"Latent tuberculosis infection:myths, models, and molecular mechanisms","volume":"78","author":"Dutta","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.tube.2014.09.001_bib53","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","article-title":"Clinical practice. Latent tuberculosis infection in the United States","volume":"364","author":"Horsburgh","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tube.2014.09.001_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-2004-829504","article-title":"Latent tuberculosis infection","volume":"25","author":"Nuermberger","year":"2004","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.tube.2014.09.001_bib55","first-page":"1","article-title":"Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions","volume":"4","author":"Opie","year":"1927","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.tube.2014.09.001_bib56","first-page":"1","article-title":"Studies on the gaseous content of tuberculous cavities","volume":"80","author":"Haapanen","year":"1959","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2014.09.001_bib57","series-title":"Tuberculosis","first-page":"101","article-title":"Persistence and drug tolerance","author":"Gomez","year":"2004"},{"key":"10.1016\/j.tube.2014.09.001_bib58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2307\/4590490","article-title":"Inapparent infection: relation of latent and dormant infections to microbial persistence","volume":"74","author":"McDermott","year":"1959","journal-title":"Public Health Rep"},{"key":"10.1016\/j.tube.2014.09.001_bib59","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Clinical practice. Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tube.2014.09.001_bib60","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1128\/JB.182.17.4889-4898.2000","article-title":"The stringent response of Mycobacterium tuberculosis is required for long-term survival","volume":"182","author":"Primm","year":"2000","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.tube.2014.09.001_bib61","doi-asserted-by":"crossref","first-page":"10026","DOI":"10.1073\/pnas.1631248100","article-title":"The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice","volume":"100","author":"Dahl","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2014.09.001_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/JB.72.2.132-141.1956","article-title":"Biochemical differentiation of Mycobacterium tuberculosis grown in\u00a0vivo and in\u00a0vitro","volume":"72","author":"Bloch","year":"1956","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.tube.2014.09.001_bib63","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/82139","article-title":"Latent Mycobacterium tuberculosis-persistence, patience, and winning by waiting","volume":"6","author":"Manabe","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2014.09.001_bib64","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.200905-0795OC","article-title":"Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection","volume":"180","author":"Zhang","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2014.09.001_bib65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201103-0397OC","article-title":"Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection","volume":"184","author":"Zhang","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2014.09.001_bib66","series-title":"Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis","author":"Singh","year":"2014"},{"key":"10.1016\/j.tube.2014.09.001_bib67","series-title":"Tuberculosis","first-page":"237","article-title":"Animal models of tuberculosis","author":"Flynn","year":"2004"},{"key":"10.1016\/j.tube.2014.09.001_bib68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1471-4914(00)01901-8","article-title":"Disease model: pulmonary tuberculosis","volume":"7","author":"McMurray","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.tube.2014.09.001_bib69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1478-811X-11-16","article-title":"Molecular immunologic correlates of spontaneous latency in a rabbit model of pulmonary tuberculosis","volume":"11","author":"Subbian","year":"2013","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.tube.2014.09.001_bib70","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1472-9792(02)00059-8","article-title":"Non-human primates: a model for tuberculosis research","volume":"83","author":"Flynn","year":"2003","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.tube.2014.09.001_bib71","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nature03419","article-title":"Ipr1 gene mediates innate immunity to tuberculosis","volume":"434","author":"Pan","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.tube.2014.09.001_bib72","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jir786","article-title":"Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions","volume":"205","author":"Harper","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.tube.2014.09.001_bib73","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/IAI.01515-07","article-title":"Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates","volume":"76","author":"Via","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.tube.2014.09.001_bib74","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1128\/AAC.02658-13","article-title":"Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis","volume":"58","author":"Lanoix","year":"2014","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib75","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1128\/AAC.02565-14","article-title":"Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas","volume":"58","author":"Irwin","year":"2014","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.tube.2014.09.001_bib76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/infdis\/jit152","article-title":"Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis","volume":"208","author":"Vilaplana","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.tube.2014.09.001_bib77","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.ajpath.2014.03.008","article-title":"Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice","volume":"184","author":"Dutta","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.tube.2014.09.001_bib78","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1128\/AAC.00120-13","article-title":"WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis","volume":"57","author":"Chang","year":"2013","journal-title":"Antimicrobial Agents Chemother"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979214205919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979214205919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T18:19:38Z","timestamp":1598293178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979214205919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1472979214205919"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2014.09.001","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thioridazine for treatment of tuberculosis: Promises and pitfalls","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}